Cryoport, Inc.(CYRX)Earnings, Financials & Key Ratios

CYRX•NASDAQ

$15.06

10.8× P/E·Price updated Jul 7, 2026

SectorIndustrials IndustryFreight & Logistics Sub-IndustryContract Logistics and Specialized Warehousing

AboutCryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.Show more

Revenue$176M-24.5%
EBITDA-$12M+86.7%
Net Income$70M+170.6%
EPS (Diluted)1.40+163.3%
Gross Margin47.14%+10.7%
EBITDA Margin-6.61%+82.4%
Operating Margin-20.89%+57.7%
Net Margin39.9%+193.5%
ROE15.54%+169.5%

CYRX Price & Volume

Cryoport, Inc. (CYRX) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operating Losses Cloud Long-Term Growth

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Strained

Cash Flow:Burning

Primary Risk:Biotech funding cycle sensitivity

Key Thesis Takeaways

Cryoport faces a challenging fundamental outlook as its reliance on volatile clinical trial volumes drives inconsistent revenue, evidenced by a 24.47% year-over-year contraction in recent periods.
While the company maintains a premium service model with gross margins between 45% and 48%, it struggles to achieve profitability due to high fixed-cost infrastructure and negative operating margins of -20.1% as of 2026Q1.
Investors should remain cautious regarding the company's ability to sustain its capital-intensive logistics operations without further eroding its $495.0M equity base.

Verdict Logic

the company's inability to convert revenue into positive operating cash flow, combined with a -20.1% operating margin in 2026Q1, suggests significant execution risk remains.

CYRX Growth Metrics

Cryoport, Inc. (CYRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years40.49%

5 Years17.49%

3 Years-7.5%

TTM-7.11%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM171.53%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM160.26%

Return on Capital

10 Years-30.81%

5 Years-5.67%

3 Years-8.13%

Last Year-6.21%

CYRX Recent Earnings

Cryoport, Inc. (CYRX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 4/12 qtrs (33%)●Beat Revenue 6/12 qtrs (50%)

Q2 2026Latest

May 4, 2026

Metric

Actual

Est

EPS

$0.23-15.0%

$0.20

Rev

$48M+6.5%

$45M

Q2 2026

Mar 3, 2026

Metric

Actual

Est

EPS

$0.21-10.5%

$0.19

Rev

$45M+6.1%

$43M

Q4 2025

Nov 4, 2025

Metric

Actual

Est

EPS

$0.18+21.7%

$0.23

Rev

$44M+3.0%

$43M

Q3 2025

Aug 5, 2025

Metric

Actual

Est

EPS

$0.29-45.0%

$0.20

Rev

$45M+9.4%

$42M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 4, 2026	$0.23vs $0.20-15.0%	$48Mvs $45M+6.5%
Q2 2026	Mar 3, 2026	$0.21vs $0.19-10.5%	$45Mvs $43M+6.1%
Q4 2025	Nov 4, 2025	$0.18vs $0.23+21.7%	$44Mvs $43M+3.0%
Q3 2025	Aug 5, 2025	$0.29vs $0.20-45.0%	$45Mvs $42M+9.4%

Based on last 12 quarters of dataView full earnings history →

Latest CYRX News

Recent stock market news and headlines for Cryoport, Inc. (CYRX)

PRNewsWire·Jun 25, 2026

Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs

IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310 NASHVILLE, Tenn., June 25, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that Cryoport Systems' IntegriCell® cryopreservation services have been selected by Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology for the treatment of solid tumors (SynKIR™-110) and B cell associated disorders and malignancies (SynKIR™-310).

Peers Comparison

Key metrics vs top competitors for Cryoport, Inc. (CYRX)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
CYRXCryoport, Inc.Current	$15.06	$755.98M	10.76	-24.47%	39.9%	15.54%	—
LQDALiquidia Corporation	$81.23	$7.22B	-101.54	1031.18%	7.74%	46.82%	—
FWRDForward Air Corporation	$13.10	$414.29M	-3.76	0.84%	-3.71%	-52.57%	—
XPOFXponential Fitness, Inc.	$6.91	$257.83M	-4.70	-1.71%	-11.1%	—	—
IARTIntegra LifeSciences Holdings Corporation	$17.46	$1.36B	-2.59	1.53%	-30.15%	-47.65%	—
UPSUnited Parcel Service, Inc.	$111.96	$95.13B	17.07	-2.49%	5.94%	32.98%	—

Compare CYRX vs Peers

Cryoport, Inc. (CYRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs LQDA

Most directly comparable listed peer for CYRX.

Scale Benchmark

vs UPS

Larger-name benchmark to compare CYRX against a more recognizable public peer.

Peer Set

Compare Top 5

vs LQDA, FWRD, XPOF, IART

CYRX SEC Filings & Documents

Cryoport, Inc. (CYRX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 4, 2026·SEC

Material company update

Mar 3, 2026·SEC

Material company update

Nov 4, 2025·SEC

10-K Annual Reports

FY 2026

Mar 5, 2026·SEC

FY 2025

Mar 7, 2025·SEC

FY 2024

Mar 13, 2024·SEC

10-Q Quarterly Reports

FY 2026

May 5, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 12, 2025·SEC

Get notified when CYRX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

CYRX Frequently Asked Questions

Cryoport, Inc. (CYRX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Cryoport, Inc.'s revenue?

Cryoport, Inc. (CYRX) reported $182.9M in revenue for fiscal year 2025. This represents a 67297% increase from $0.3M in 2003.

How fast is Cryoport, Inc. growing?

Cryoport, Inc. (CYRX) saw revenue decline by 24.5% over the past year.

Is CYRX profitable?

Yes, Cryoport, Inc. (CYRX) is profitable, generating $77.1M in net income for fiscal year 2025 (39.9% net margin).

Dividend & Returns

What is CYRX's return on equity?

Cryoport, Inc. (CYRX) has a return on equity (ROE) of 15.5%. This is reasonable for most industries.

What is Cryoport, Inc.'s free cash flow?

Cryoport, Inc. (CYRX) had negative free cash flow of $17.8M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in CYRX back in 2003?

Total return calculator · dividends reinvested · 23+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 4, 2026

$0.23vs $0.20-15.0%

$48Mvs $45M+6.5%

Q2 2026

Mar 3, 2026

$0.21vs $0.19-10.5%

$45Mvs $43M+6.1%

Q4 2025

Nov 4, 2025

$0.18vs $0.23+21.7%

$44Mvs $43M+3.0%

Q3 2025

Aug 5, 2025

$0.29vs $0.20-45.0%

$45Mvs $42M+9.4%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

CYRXCryoport, Inc.Current

$15.06

$755.98M

10.76

-24.47%

39.9%

15.54%

—

LQDALiquidia Corporation

$81.23

$7.22B

-101.54

1031.18%

7.74%

46.82%

—

FWRDForward Air Corporation

$13.10

$414.29M

-3.76

0.84%

-3.71%

-52.57%

—

XPOFXponential Fitness, Inc.

$6.91

$257.83M

-4.70

-1.71%

-11.1%

—

IARTIntegra LifeSciences Holdings Corporation

$17.46

$1.36B

-2.59

1.53%

-30.15%

-47.65%

—

UPSUnited Parcel Service, Inc.

$111.96

$95.13B

17.07

-2.49%

5.94%

32.98%

—